Intravitreal ranibizumab for choroidal neovascularization associated with retinal astrocytic hamartoma.
OBJECTIVE
To report on a patient with retinal astrocytic hamartoma, who developed a choroidal neovascularization (CNV), effectively treated by intravitreal ranibizumab injections.


METHODS
A 74-year-old woman who, 12 years before, had been diagnosed with a yellow-gray lesion in the left eye (OS) presented in our department for OS decreased vision of recent onset.


RESULTS
Upon a complete ophthalmologic examination including ultrasonography, fluorescein angiography (FA), and spectral domain optical coherence tomography (SD-OCT), the patient was diagnosed with retinal astrocytic hamartoma and coincident CNV on its foveal border. Six months after 3 monthly intravitreal ranibizumab injections, FA and OCT revealed the CNV closure and absence of intraretinal and subretinal fluid on the foveal border of the retinal astrocytic hamartoma.


CONCLUSIONS
Associations between retinal astrocytic hamartoma and CNV have not been previously reported. Intravitreal ranibizumab injection appears an attractive therapeutic option for patients showing such an unusual association.
Querques
Giuseppe
G
Department of Ophthalmology, Hopital Intercommunal de Creteil, University Paris XII, Paris, France. giuseppe.querques@hotmail.it
Kerrate
Houda
H
Leveziel
Nicolas
N
Coscas
Gabriel
G
Soubrane
Gisele
G
Souied
Eric H
EH
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006222:Hamartoma / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D058449:Intravitreal Injections; D000069579:Ranibizumab; D012164:Retinal Diseases / Q000150:complications* / Q000175:diagnosis; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab